Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suxiao Jiuxin Pills is a traditional Chinese medicine formulation widely used in China for the treatment of cardiovascular diseases such as angina pectoris and coronary heart disease. Developed in the 1980s by Chenggui Zhang, it is composed primarily of two herbal ingredients: Ligusticum chuanxiong Hort. (Chuanxiong) and Borneolum syntheticum (Borneol). The main active constituents include phthalides (such as senkyunolide A), phenolic acids (ferulic acid), alkaloids (ligustrazine/tetramethylpyrazine), and borneol. Mechanistically, these compounds exert vasodilatory effects by relaxing vascular smooth muscle—likely through modulation of calcium channels and potassium channels—and improving myocardial blood supply. The pill has demonstrated efficacy in relieving angina symptoms rapidly without significant side effects and may also improve microcirculation, reduce inflammation, support endothelial function, inhibit arrhythmias via potassium channel blockade (notably hKv1.5), and provide cardioprotective effects against ischemia-reperfusion injury[1][2][3][6][7]. It is included on China's national essential drug list for cardiocerebral vascular diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suxiao Jiuxin Pills.